New leukemia drug is more effective and easier to use - (ScienceDaily via NewsPoints Desk)

  • Research data published in the NEJM support the efficacy and ease of use of Imbruvica in elderly patients with chronic lymphocytic leukaemia (CLL), ScienceDaily reported Friday.

  • In the study, the investigators randomised 547 patients with CLL to treatment with Imbruvica, the standard treatment consisting of bendamustine plus rituximab or Imbruvica plus rituximab.

  • The researchers found that 87 percent of patients who received Imbruvica monotherapy were alive without disease progression after two years, versus 74 percent for patients who received standard treatment.

  • Meanwhile, the research team noted that the addition of rituximab to Imbruvica did not improve progression-free survival versus Imbruvica alone.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.